Synergistic Anticancer Effect by Targeting CDK2 and EGFR-ERK Signaling.
Jinhuan Wu,Yuping Chen,Rui Li,Yaping Guan,Mu Chen,Hui Yin,Xiaoning Yang,Mingpeng Jin,Bingsong Huang,Xin Ding,Jie Yang,Zhe Wang,Yiming He,Qianwen Wang,Jian Luo,Ping Wang,Zhiyong Mao,Michael S. Y. Huen,Zhenkun Lou,Jian Yuan,Fanghua Gong
DOI: https://doi.org/10.1083/jcb.202203005
2023-01-01
Abstract:The EGFR-RAS-ERK pathway is one of the most important signaling cascades in cell survival, growth, and proliferation. Aberrant activation of this pathway is a common mechanism in various cancers. Here, we report that CDK2 is a novel regulator of the ERK pathway via USP37 deubiquitinase (DUB). Mechanistically, CDK2 phosphorylates USP37, which is required for USP37 DUB activity. Further, USP37 deubiquitinates and stabilizes ERK1/2, thereby enhancing cancer cell proliferation. Thus, CDK2 is able to promote cell proliferation by activating USP37 and, in turn, stabilizing ERK1/2. Importantly, combined CDK1/2 and EGFR inhibitors have a synergetic anticancer effect through the downregulation of ERK1/2 stability and activity. Indeed, our patient-derived xenograft (PDX) results suggest that targeting both ERK1/2 stability and activity kills cancer cells more efficiently even at lower doses of these two inhibitors, which may reduce their associated side effects and indicate a potential new combination strategy for cancer therapy.